The Pharmaceuticals Division focuses on prescription drugs for the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. With its innovative pharmaceutical products, Bayer seeks to achieve a significant therapeutic benefit for patients while at the same time satisfying the growing requirements of physicians and health insurers. The Pharmaceuticals division in China is headquartered in Beijing with facilities in Beijing and Guangzhou. In anticipation of increasing product demand in China, Bayer invested EUR 100 million to significantly increase the production capacity of its Beijing plant. The capacity extension is designed to ensure a reliable supply of high-quality products to meet the Chinese market’s demand for pharmaceutical products, including the company’s cardiovascular and anti-diabetes products. The Pharmaceuticals Division’s Radiology business is a world-well-known diagnostic imaging solutions provider. In the field of Radiology, Bayer provides solution with imaging contrast media, injection devices and informatics in China.
Consumer Health Division
Bayer’s Consumer Health Division is an important player in the global consumer health marketplace. It operates in more than 100 countries and maintains several manufacturing and research-and-development (R&D) sites.
The division’s rich history of innovation began in 1899 with the introduction of Bayer’s well-known global consumer brand, Bayer Aspirin™. In 2005, Bayer acquired Roche’s OTC business and in October 2014 Bayer completed the acquisition of Merck’s global Consumer Care business. In November 2014, Bayer acquired 100 percent of the shares of the Chinese Dihon Pharmaceutical Group Co., Ltd.
Besides the over-the-counter (OTC) manufacturing sites in Shanghai, Qidong and Kunming, Bayer announced in January 2016 a milestone opening of its state-of-the-art manufacturing site of traditional Chinese medicine and western medicine in the Majinpu bioengineering and pharmaceutical industrial park in Yunnan. The site is Bayer’s second largest OTC manufacturing facility in Asia Pacific, which will greatly enhance the company’s integral capabilities in providing high-quality self-care solutions to meet the diverse healthcare needs of Chinese consumers.
Today, the Consumer Health divison offers to consumers some of the world’s well-known and trusted medications and dietary supplements. The portfolio includes strong brands in various medical categories in which the company competes, including Allergy, Analgesics, Cardiovascular Risk Prevention, Cough & Cold, Dermatology, Gastrointestinals, Dietary Supplements.
Currently, the Consumer Health Division sells various influential brands on the Chinese market, including Talcid®, Elevit®, Kangwang®, Clarityne®, Eloson®, Pikangwang®, White & Black®, Canesten®, Redoxon®, and others.
Crop Science Division
The Crop Science Division, a world-well-known crop protection solution provider, is committed to contributing to a sustainable development of agriculture by introducing innovation into the market. With a highly efficient and innovative portfolio, complete technical services and strong collaborations with local partners, the Crop Science Division China is aligned with the Chinese government’s efforts to modernize Chinese agriculture and dedicated to help farmers improve plant health, get better yields and gain more benefits.
Bayer has been active for over 60 years in Chinese agriculture, marked with constant efforts to introduce new technologies to Chinese farmers, ranging from Decis, an insecticide in early 1980s, to Luna Sensation launched in 2014, a fungicide for a wide range of vegetables and fruit. In March 2015, Crop Science launched 6 new innovative products in China covering crops of rice, corn, wheat, vegetables and fruits. In a total, over 20 new products are planned to be launched by 2020.
As a global player, Bayer’s production site in Hangzhou is not only supplying products for domestic use, but also manufacturing for farmers in Asia and North and Latin America.
The Crop Science Division has also been carrying out projects in cooperation with authorities like the Ministry of Agriculture, the Chinese Academy of Agricultural Sciences as well as joint efforts with public partners on capacity building in agriculture. To support the latest government efforts in rural development, Bayer started collaboration with CITIC Trust in February 2014 on Innovation & Development of Modern Agricultural Technology on the background of Land Transfer. The collaboration aims to introduce financial services via the CITIC Trust, together with technology and innovation through Crop Science to Chinese agriculture, leveraging the rich experience and expertise of the two parties.
In the field of animal health, it offers a number of products for farm and companion animals. Bayer is a successful supplier of veterinary products in China with its head office and a GMP certified plant in Chengdu, Sichuan province.